Today's Health Care Gainers Led By Watson Pharmaceuticals Inc. (WPI)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Watson Pharmaceuticals ( WPI) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.2%. By the end of trading, Watson Pharmaceuticals rose $1.35 (1.4%) to $97.19 on average volume. Throughout the day, 1.1 million shares of Watson Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock ranged in a price between $94.75-$97.41 after having opened the day at $95.19 as compared to the previous trading day's close of $95.84. Other companies within the Health Care sector that increased today were: Biocryst Pharmaceuticals ( BCRX), up 28.8%, Hemispherx Biopharma ( HEB), up 15.5%, Iridex Corporation ( IRIX), up 15%, and Fonar Corporation ( FONR), up 10.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. Watson Pharmaceuticals has a market cap of $10.95 billion and is part of the drugs industry. The company has a P/E ratio of 13.9, below the S&P 500 P/E ratio of 17.7. Shares are down 1.5% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Watson Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Watson Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Rigel Pharmaceuticals ( RIGL), down 40.2%, Cardium Therapeutics ( CXM), down 24.7%, Zogenix ( ZGNX), down 12.6%, and Enzo Biochem ( ENZ), down 8.9%, were all laggards within the health care sector with Medtronic ( MDT) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Watson Rises On Unusually High Volume (WPI)

5 Drugs Stocks On The Rise

Watson Stock Hits New 52-Week High (WPI)

Watson Rises On Unusually High Volume (WPI)

Watson Reaches New 52-Week High (WPI)